Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FLT3 |
Variant | A627T |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FLT3 A627T lies within the protein kinase domain of the Flt3 protein (UniProt.org). A627T has been identified as a drug resistance mutation (PMID: 15374944, PMID: 17620426), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Dec 2023). |
Associated Drug Resistance | Y |
Category Variants Paths |
FLT3 mutant FLT3 exon15 FLT3 A627T |
Transcript | NM_004119.3 |
gDNA | chr13:g.28033950C>T |
cDNA | c.1879G>A |
Protein | p.A627T |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004119.2 | chr13:g.28033950C>T | c.1879G>A | p.A627T | RefSeq | GRCh38/hg38 |
NM_004119 | chr13:g.28033950C>T | c.1879G>A | p.A627T | RefSeq | GRCh38/hg38 |
NM_004119.3 | chr13:g.28033950C>T | c.1879G>A | p.A627T | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins FLT3 A627T | hematologic cancer | predicted - resistant | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing a FLT3-ITD mutation with FLT3 A627T demonstrated moderate resistance to treatment with Rydapt (midostaurin) in culture (PMID: 15374944). | 15374944 |
FLT3 exon 14 ins FLT3 A627T | hematologic cancer | predicted - resistant | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing a FLT3-ITD mutation with FLT3 A627T demonstrated resistance to Rydapt (midostaurin) in culture (PMID: 17620426). | 17620426 |
FLT3 exon 14 ins FLT3 A627T | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Biochemical | Actionable | In a preclinical study, PHI-101 demonstrated activity against FLT3 A627T in the context of a FLT3-ITD mutation in culture (Cancer Res 2020;80(16 Suppl):Abstract nr 4226). | detail... |